The vaccine story is set to take yet another twist and turn in the months ahead as the Biden administration faces the literally world-shaping task of playing a material leadership role in helping to vaccinate the entire world against Covid-19.

This comes after better-than-expected results in the pathway to bringing something rapidly closing in on vaccine-induced herd immunity to the United States over recent months.

According to a recent piece in the Wall Street Journal, this new effort is being marshaled by Jeffrey Zients, the U.S. coronavirus response coordinator. To win the battle at home, Zients and his team bought up such a large supply that the US vaccination effort couldn’t be derailed even in the face of bottlenecks and other speed bumps along the way.

But the same solution is hardly likely to work for the rest of the world, especially in the poorer and more densely populated nations.

According to researchers at Duke University, it would take about 11 billion vaccine doses to supply enough to get the rest of the world to herd immunity — about 70% poked.

A quote from Mr. Zients says the important idea here: “America will never be fully safe until the pandemic is under control both at home and around the world.” This is the same idea now passing through the minds of top officials in every major developed-world country.

But how do you get those 11 billion doses? And, more importantly, once you have them, and then a new variant pops up that demands revaccinating the world with a new “vaccine 2.0” solution to expand our collective immunity shield, how do you do it again? How about a third time a couple of years later?

At this point, from publicly available materials, the producers of the current top vaccines don’t have a solution for this problem — it isn’t going to come from Pfizer Inc (NYSE: PFE), Novavax Inc (NASDAQ: NVAX), Moderna Inc (NASDAQ: MRNA), AstraZeneca plc (NYSE: AZN), Johnson & Johnson (NYSE: JNJ), or BioNTech SE – ADR (NASDAQ: BNTX).

But there is another smaller name that is carving out a possible solution pathway that has yet to get much of a spotlight from the market:  Dyadic International Inc (NASDAQ: DYAI).


The Fast Lane?

Dyadic International Inc (NASDAQ: DYAI) has a new approach that could become a better way to deal with new variants and even possibly better able to drive cheap and efficient production capable of vaccinating the world.

DYAI has developed a biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), also known as “C1”.

In a recent update, it was revealed that the company’s technology was able to produce an antigen solution for SBV that was hundreds of times more scalable and stable than antigens produced through a traditional vector.

The company has now started to move toward collaborations that could produce the next major breakthrough in fighting Covid-19 over the long term, including vaccines that cover Covid-19 variants. In fact, DYAI believes it can produce trivalent and quadrivalent Covid-19 vaccines – ie a single vaccine that can cover three or even four variants of the virus simultaneously.

According to materials published by Dyadic International Inc (NASDAQ: DYAI), the C1 microorganism enables the development and large-scale manufacture of low-cost proteins and has the potential to be further developed into a safe and efficient expression system that may help speed up the development of biologic vaccines and drugs at commercial scales, while lowering production costs and improving performance at the same time.

The key in all of this is that the company’s platform may enable a much more scalable production model for Covid-19 vaccines.


A Vax for All Seasons?

Dyadic International Inc (NASDAQ: DYAI) is also working toward the development of its own proprietary vaccine for Covid-19, DYAI-100.

According to its recent summary, the company has taken defining steps toward its goal of launching a first-in-human Phase 1 clinical trial for DYAI-100 so far this year.

DYAI-100 is supported by a strategic collaboration with, among other parties, the IIBR and leading infectious disease scientists from Erasmus Medical Centre, University Utrecht, TiHo Hannover (scientists who were involved in the ZAPI program) to develop a temperature stable, safe, and effective COVID-19 vaccine candidate that can be rapidly manufactured, in large quantities, at low cost, using standard microbial fermenters that are readily available globally.

DYAI also engaged CR2O in March. CR2O is a leading contract research organization engaged to manage and support further preclinical and clinical development of DYAI-100. The animal GLP toxicology study began at the end of April 2021, the cGMP production of the C1 expressed SARS-CoV-2 RBD drug product has begun, and a first-in-human Phase 1 clinical trial is expected to begin by year-end.

As noted in the company’s release, there are a number of benefits the Company expects to come from the DYAI-100 Phase 1 clinical trial, including demonstrating that certain C1 produced proteins can be produced under cGMP conditions and are safe and tolerated in humans, which will be required by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

This will also serve as a proof-of-concept study for potential C1 manufactured next-generation monovalent and multivalent COVID-19 variant vaccine candidates that can be developed and manufactured rapidly, in large quantities, and more affordably.

The end goal there is the development of a vaccine approach capable of having a wider valency for variant coverage as well as compatibility with the C-1 fungal production vector platform approach, potentially (and hopefully) helping to more rapidly scale-up a robust defense capable of reaching around the world in a short period.


DISCLAIMER:  EDM Media LLC (EDM), is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  EDM is NOT affiliated in any manner with any company mentioned herein.  EDM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses, and may NOT sell, offer to sell, or offer to buy any security.  EDM’s market updates, news alerts, and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  EDM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed, EDM has been compensated six thousand dollars for news coverage of the current press releases issued by Dyadic International Inc (NASDAQ: DYAI) by a third party.


This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and EDM undertakes no obligation to update such statements.






Media Contact:


Email: IR@EDM.Media

Office: 800-301-7883



Related Post

No Comments

Leave a Comment

Recent Posts

Recent Posts

Contact Us

All Rights Reserved © 2019